Alirocumab-associated unilateral posterior uveitis
Abstract
A man in his mid-40s who had been recently started on alirocumab (a human monoclonal antibody which inhibits proprotein convertase subtilisin/kexin type 9) due to his strong familial cardiovascular risk and refractory hypercholesterolaemia presented with a few-hour history of acute-onset left-sided blurred vision. The best-corrected visual acuities were 6/6 bilaterally and slit-lamp examination was normal. However, optical coherence tomography revealed serous subretinal fluid in the left macula. Optos ultra-widefield retinal imaging and fundus autofluorescence, along with a set of blood tests, did not reveal any alternative causes. A diagnosis of alirocumab-associated uveitis was diagnosed. Alirocumab was stopped and he was followed up in uveitis clinic. Within 4 months following alirocumab cessation, the subretinal fluid resolved completely. This case report emphasises the importance of early multidisciplinary team involvement, since novel therapeutic agents can have unexpected adverse events.
Citations
Altmetric:
Date
2024-01-24
Type
Article
Subject
Ophthalmology, Cardiology
Collections
Citation
Inegbedion ES, Azzopardi M, Inessa T, Chong YJ. Alirocumab-associated unilateral posterior uveitis. BMJ Case Rep. 2024 Jan 24;17(1):e258183. doi: 10.1136/bcr-2023-258183
Journal / Source Title
BMJ Case Reports
DOI
10.1136/bcr-2023-258183
PMID
38272519
Publisher
BMJ Publishing Group